Clinical Scorecard: Pentraxin-3 as a Systemic Indicator of Pathology and a Local Inflammatory Mediator in Thyroid Nodules

At a Glance

Key Highlights

• Preoperative plasma PTX3 levels were significantly elevated compared to normal reference range.
• PTX3 expression was significantly elevated in malignant tissues relative to healthy thyroid tissues.
• No significant differences in plasma PTX3 levels were observed between benign and malignant conditions.
• Increased PTX3 levels may indicate an active inflammatory response linked to thyroid nodular disease.
• Further studies are needed to define the prognostic value of PTX3 in thyroid carcinoma.

Guideline-Based Recommendations

Diagnosis

• Surgical indications for thyroid nodules include suspicious or malignant cytology on fine-needle aspiration.

Management

• Thyroidectomy is indicated for nodular thyroid disease requiring surgical intervention.

Monitoring & Follow-up

• Plasma PTX3 levels should be assessed preoperatively and postoperatively.

Risks

• Potential for misclassification of benign vs malignant nodules based on PTX3 levels.

Patient & Prescribing Data

Patients with nodular thyroid disease requiring surgical intervention.

PTX3 levels may serve as a marker for inflammation but lack specificity for malignancy.

Clinical Best Practices

• Evaluate PTX3 levels in patients undergoing thyroid surgery.
• Consider the role of PTX3 in the inflammatory response associated with thyroid nodules.

Related Resources & Content

• Pentraxin-3 and Thyroid Nodules Study